Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | The state of CAR T-cell products today

Nitin Jain • 12 Sep 2018
SOHO 2018
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Leukemia CAR-T

Nitin Jain, MD, discusses the CAR T-cell program at the MD Anderson Cancer Center, Houston, TX. He highlights the diseases for which CAR T-cells are being applied, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). He also evaluates the costs and benefits associated with autologous CAR T-cells versus allogenic, off the shelf therapies, giving examples of the key products on the market today. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.

More from Nitin Jain

1:13
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain • 10 Dec 2023
1:06
An ongoing Phase I trial evaluating AS-1763, a novel non-covalent BTKi, in B-cell lymphomas
Nitin Jain • 10 Dec 2023
1:43
Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL
Nitin Jain • 10 Dec 2023
1:54
Nivolumab + ibrutinib for patients with Richter’s transformation
Nitin Jain • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals